AbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoon

AbbVie has signed a deal worth up to $2.4 billion with the US biotech Harpoon Therapeutics, expanding a research and licensing collaboration involving technology that trains T-cells to target BCMA, a biomarker associated with multiple myeloma.